CroíValve adds $20m to Series B, taking round to $36m

Poznan University of Medical Sciences and CroíValve teams following DUO Adapt cases. Image Croivalve

New investors BGF have joined the round, which will fund an expanded US and EU clinical study of CroíValve’s Duo Tricuspid Coaptation Valve System.

Trinity College Dublin medical device spin-out company CroíValve has closed a $20m Series B expansion, to add to its $7m million European Innovation Council (EIC) and DTIF grant financing, bringing the total for its Series B to $36 million, and $43M including grant financing.

CroíValve’s new financing includes new investors BGF, along with participation from current investors including the MedTech Syndicate.

CroíValve is a clinical-stage medtech developing a minimally invasive device to treat tricuspid regurgitation – a severe cardiac disease.